Analyst firms · Morgan Stanley · ABT

Morgan Stanley ABT price target and rating history

Abbott Laboratories (ABT) · Health Care

Morgan Stanley rates Abbott Laboratories (ABT) Equal-Weight with a $112 price target, as of its latest action on May 30, 2023. It has published 5 rating actions on ABT since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

Current rating
Equal-Weight
Price target
$112
Median target, all firms
$121
Actions on ABT
5

Morgan Stanley price target on ABT

$157$135$11220222023202420252026
Morgan Stanley price target on ABT, each point a stated target, July 2021 to May 2023.

Every Morgan Stanley rating on ABT

How other firms rate ABT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchHoldOct 27, 2026
BarclaysOverweight$120Oct 7, 2026
Rothschild & Co RedburnBuy$127Oct 2, 2026
Wolfe ResearchOutperform$130Aug 13, 2026
Robert W. BairdOutperform$121Jul 1, 2026
DaiwaNeutral$92Apr 22, 2026

Questions about Morgan Stanley and ABT

What is Morgan Stanley's price target for ABT?
Morgan Stanley's latest stated price target for Abbott Laboratories (ABT) is $112, from its action on May 30, 2023.
What is Morgan Stanley's rating on ABT?
Morgan Stanley rates ABT Equal-Weight, a neutral rating, as of May 30, 2023.
When did Morgan Stanley last change its view on ABT?
On May 30, 2023, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $112.
How does Morgan Stanley's ABT target compare with other analysts?
Across 5 firms with a ABT price target in the last 12 months, the median target is $121.

More ABT rating histories

All Morgan Stanley ratingsABT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.